SYK Stock Analysis: Stryker | NYSE
Medical Devices | NYSE, USA | Market Cap: 116.273m USD | 12M Return: -28.4% | US8636671013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 813M
EPS Trend: 98.7%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stryker Corporation (NYSE: SYK) is a U.S.-based medical technology company headquartered in Portage, Michigan, operating two reportable segments: MedSurg & Neurotechnology and Orthopaedics. Its MedSurg & Neurotechnology segment supplies surgical equipment, navigation and communications systems, patient handling and emergency care products, stroke treatment devices, and orthobiologic and biosurgery products. The Orthopaedics segment offers implants for hip, knee, shoulder, ankle, and trauma/extremities procedures, along with the Mako robotic-assisted surgery platform. Products are sold directly through company-owned subsidiaries and branches, as well as through third-party dealers and distributors across roughly 61 countries. The company was founded in 1941 and is classified within the GICS Health Care Equipment sub-industry as a large-cap stock.
As a diversified medical device manufacturer, Stryker combines capital equipment sales (such as surgical navigation systems and Mako robots) with recurring revenue from higher-margin consumables and implant replenishment, a common business model in the medtech sector that helps offset the longer sales cycles of large capital purchases. Demand is largely driven by demographic trends such as aging populations in developed markets, which supports steady growth in joint replacement and surgical volumes.
- Mako robotic adoption accelerates Orthopaedics revenue growth
- Hospital capital spending weakness pressures MedSurg equipment orders
- Acquisitions expand Neurotechnology portfolio and boost margins
| Net Income: 3.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.12 > 1.0 |
| NWC/Revenue: 29.93% < 20% (prev 23.99%; Δ 5.94% < -1%) |
| CFO/TA 0.12 > 3% & CFO 5.53b > Net Income 3.73b |
| Net Debt (11.5b) to EBITDA (6.91b): 1.66 < 3 |
| Current Ratio: 2.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (386.0m) vs 12m ago -0.10% < -2% |
| Gross Margin: 65.17% > 18% (prev 62.19%; Δ 2.98% > 0.5%) |
| Asset Turnover: 54.82% > 50% (prev 51.41%; Δ 3.41% > 0%) |
| Interest Coverage Ratio: 6.88 > 6 (EBIT TTM 5.69b / Interest Expense TTM 827.0m) |
| A: 0.16 (Total Current Assets 14.4b - Total Current Liabilities 6.68b) / Total Assets 47.9b |
| B: 0.46 (Retained Earnings 21.8b / Total Assets 47.9b) |
| C: 0.12 (EBIT TTM 5.69b / Avg Total Assets 47.1b) |
| D: 1.00 (Book Value of Equity 24.0b / Total Liabilities 23.9b) |
| Altman-Z'' = 4.41 = AA |
| DSRI: 0.88 (Receivables 3.74b/3.92b, Revenue 25.8b/23.8b) |
| GMI: 0.95 (GM 62.19% / 65.17%) |
| AQI: 0.97 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.08 (Revenue 25.8b / 23.8b) |
| TATA: -0.04 (NI 3.73b - CFO 5.53b) / TA 47.9b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of September 15, 2026, the stock is trading at USD 275.56 with a total of 3,714,339 shares traded. Over the past week, the price has changed by -10.53%, over one month by -20.85%, over three months by -9.60% and over the past year by -28.40%.
Current recommended Stop Loss: 261.10 (which is 5.2% or 1.3 ATR below the current price).
Stryker has received a consensus analysts rating of 4.06. Therefore, it is recommended to buy SYK.
- StrongBuy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 382.7 | 38.9% |
P/E Trailing = 31.445
P/E Forward = 18.4162
P/S = 4.5002
P/B = 4.9248
P/EG = 1.3064
Revenue TTM = 25.8b USD
EBIT TTM = 5.69b USD
EBITDA TTM = 6.91b USD
Long Term Debt = 14.2b USD (from longTermDebt, last quarter)
Short Term Debt = 750.0m USD (from shortTermDebt, last quarter)
Debt = 14.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.5b USD (calculated: Debt 14.9b - CCE 3.48b)
Enterprise Value = 128b USD (116b + Debt 14.9b - CCE 3.48b)
Interest Coverage Ratio = 6.88 (Ebit TTM 5.69b / Interest Expense TTM 827.0m)
EV/FCF = 27.17x (Enterprise Value 128b / FCF TTM 4.70b)
FCF Yield = 3.68% (FCF TTM 4.70b / Enterprise Value 128b)
FCF Margin = 18.20% (FCF TTM 4.70b / Revenue TTM 25.8b)
Net Margin = 14.43% (Net Income TTM 3.73b / Revenue TTM 25.8b)
Gross Margin = 65.17% ((Revenue TTM 25.8b - Cost of Revenue TTM 9.00b) / Revenue TTM)
Gross Margin QoQ = 68.27% (prev 63.29%)
Tobins Q-Ratio = 2.67 (Enterprise Value 128b / Total Assets 47.9b)
Interest Expense / Debt = 5.53% (Interest Expense 827.0m / Debt 14.9b)
Taxrate = 27.56% (1.42b / 5.15b)
NOPAT = 4.12b (EBIT 5.69b * (1 - 27.56%))
Current Ratio = 2.16 (Total Current Assets 14.4b / Total Current Liabilities 6.68b)
Debt / Equity = 0.62 (Debt 14.9b / totalStockholderEquity, last quarter 24.0b)
Debt / EBITDA = 1.66 (Net Debt 11.5b / EBITDA 6.91b)
Debt / FCF = 2.44 (Net Debt 11.5b / FCF TTM 4.70b)
Total Stockholder Equity = 22.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.91% (Net Income 3.73b / Total Assets 47.9b)
RoE = 16.36% (Net Income TTM 3.73b / Total Stockholder Equity 22.8b)
RoCE = 15.39% (EBIT 5.69b / Capital Employed (Equity 22.8b + L.T.Debt 14.2b))
RoIC = 10.13% (NOPAT 4.12b / Invested Capital 40.7b)
WACC = 6.62% (E(116b)/V(131b) * Re(6.96%) + D(14.9b)/V(131b) * Rd(5.53%) * (1-Tc(0.28)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 75.43 | Cagr: 0.10%
[DCF] Terminal Value 77.97% ; FCFF base≈4.43b ; Y1≈5.08b ; Y5≈7.48b
[DCF] Fair Price = 263.4 (EV 112b - Net Debt 11.5b = Equity 101b / Shares 383.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.75 | EPS CAGR: 12.24% | SUE: 1.38 | # QB: 1
Revenue Correlation: 99.77 | Revenue CAGR: 10.21% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.59 | Chg30d=+0.72% | Revisions=-78% | Analysts=24
EPS current Year (2026-12-31): EPS=15.02 | Chg30d=+0.06% | Revisions=+65% | GrowthEPS=+10.2% | GrowthRev=+8.7%
EPS next Year (2027-12-31): EPS=16.75 | Chg30d=-0.05% | Revisions=+48% | GrowthEPS=+11.6% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +16% (up=38, down=27)